Trial Profile

A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efavaleukin alfa (Primary)
Indications Ulcerative colitis
Focus Adverse reactions
Sponsors Amgen

Most Recent Events

25 Nov 2024 According to ClinicalTrials.gov: US National Institutes of Health,this trial is terminated as the parent study 20170104 was terminated due to the study meeting a prespecified futility rule. Consequently, this study was terminated
25 Nov 2024 Status changed from active, no longer recruiting to discontinued.
27 Sep 2024 Planned End Date changed from 27 Jan 2028 to 15 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com